Calcium channel blockers (CCB) are a common class of medication used to treat high blood pressure and heart arrhythmias (irregular heartbeats). Calcium is a mineral that is vital for heart muscle ...

The best ad blockers are unfortunately very necessary to survive on the modern internet. It doesn't matter which sites you browse, there's the risk of being harassed by pop-ups, tracker cookies ...

Childhood obesity, defined as an age-adjusted and sex-adjusted body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) in the 95th percentile or higher ...

Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a ...

Obesity is common worldwide and continues to increase in prevalence. GLP-1 receptor agonists were developed for the treatment of diabetes but have revolutionised the treatment of obesity, consistently ...

The adenosine–adenosine receptor pathway plays important roles in the immune system and inflammation. Four adenosine receptors (i.e., A1R, A2AR, A2BR, and A3R) have been identified. However, the roles ...

Exploration of adenosine mechanism revealed adenosine receptors as a potentially useful target of therapy in RA.

Long-term use of beta-blockers in patients with myocardial infarction and preserved heart function does not significantly change quality of life or well-being compared to no beta-blockers.

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Glucagon-like peptide-1 ...

Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations.